Monte Rosa rises on lining up new combo trial in advanced prostate cancer

Monte Rosa Therapeutics

16/03/2026 11:10

** Shares of biotech firm Monte Rosa Therapeutics GLUE.O rise 5.1% to $16.85 premarket

** Co says it will start a mid‑stage study of its experimental prostate cancer drug MRT‑2359 with Johnson & Johnson’s JNJ.N Erleada

** Trial will test the combo in men with advanced prostate cancer that no longer responds to hormone therapy, a hard‑to‑treat stage of the disease - GLUE

** MRT‑2359 is an oral experimental drug designed to break down a protein that helps cancer cells survive, co says

** Study expected to begin in the third quarter of 2026 and enroll up to 25 patients, with Monte Rosa running the trial and J&J supplying Erleada - GLUE

** Erleada is already approved for certain prostate cancers; study will track PSA levels, tumor size and disease progression, co says

** Shares up about two fold in 2025

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))